IPHASE產(chǎn)品HGPRT基因突變?cè)噭┖兄蒲性核l(fā)表重要文章
近日，北京大學(xué)使用IPHASE品牌產(chǎn)品：HGPRT 基因突變?cè)噭┖性凇禨cience Advances》權(quán)威期刊上發(fā)表文章《Pt-seq unveils the genomic binding pattern of platinum-based drugs》，影響因子12.5！
【摘要】
Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genomewide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatinDNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt–DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs.
完整版文獻(xiàn)可在【IPHASE】公眾號(hào)后臺(tái)留言【獲取文章】
再次恭喜文獻(xiàn)發(fā)表，以及對(duì)我司產(chǎn)品的認(rèn)可，希望以上文獻(xiàn)能幫助大家了解目前研究進(jìn)展及我們的核心技術(shù)，歡迎各位新老客戶聯(lián)系我們咨詢、提出意見，愿我們的努力成果與您的科研碰撞出不一樣的火花！
【摘要】
Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genomewide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatinDNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt–DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs.
完整版文獻(xiàn)可在【IPHASE】公眾號(hào)后臺(tái)留言【獲取文章】
再次恭喜文獻(xiàn)發(fā)表，以及對(duì)我司產(chǎn)品的認(rèn)可，希望以上文獻(xiàn)能幫助大家了解目前研究進(jìn)展及我們的核心技術(shù)，歡迎各位新老客戶聯(lián)系我們咨詢、提出意見，愿我們的努力成果與您的科研碰撞出不一樣的火花！
- 普瑞邦邀您參加真菌毒素檢測(cè)技術(shù)交流會(huì)
- 奎克泰推出中性粒細(xì)胞胞外誘捕網(wǎng)(NETs)檢測(cè)試劑盒
- 慶祝西美杰榮獲科興“聚勢(shì)•卓越貢獻(xiàn)獎(jiǎng)”
- IPHASE/匯智和源亮相BIONNOVA生物醫(yī)藥創(chuàng)新者論壇
- IPHASE——?jiǎng)?chuàng)新藥體外評(píng)價(jià)生物試劑國(guó)產(chǎn)替代先行者
- IPHASE精彩亮相BIOCHINA2025易貿(mào)生物產(chǎn)業(yè)展覽
- IPHASE邀您相聚第64屆美國(guó)毒理學(xué)會(huì)年會(huì)SOT 2025
- IPHASE亮相第十四屆藥理學(xué)會(huì)藥物和化學(xué)異物代謝會(huì)議
Copyright(C) 1998-2026 生物器材網(wǎng) 電話：021-64166852;13621656896 E-mail：info@bio-equip.com